Group 1 - Hong Kong innovative drug concept stocks saw significant gains in early trading, with companies like Ascentage Pharma-B, CanSino Biologics, Kelun-Biotech, and Zai Lab rising over 5% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net inflow of over 17 million yuan recently, reaching a historical high in scale, with nearly 200 million yuan added in June alone [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index announced a revision to its compilation scheme, focusing solely on innovative drug companies, achieving a 100% "purity" in its index [1] Group 2 - Major multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China, with the procurement amount from January to May nearing the total for the entire year of 2024, indicating the competitiveness of China's innovative drugs in the international market [2] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with its scale surpassing 400 million yuan, providing investors with opportunities in the innovative drug industry [2]
港股创新药早盘走高，“纯度”100%的恒生创新药ETF（159316）标的指数大涨超2%，昨日吸金逾1700万元
Mei Ri Jing Ji Xin Wen·2025-07-03 02:48